Cargando…

Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator

Pulmonary artery hypertension (PAH) occurs when mean pulmonary artery pressure (PAP) is higher than 25 mmHg in rest or 30 mmHg during activity. Idiopathic pulmonary artery hypertension (IPAH) is defined as PAH without a definite reason. The IPAH is a rare disease with a high mortality rate if left u...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharif-Kashani, Babak, Serati, Alireza, Shafaghi, Shadi, Behzadnia, Neda, Naghashzadeh, Farah, Keshmiri, Mohammad Sadegh, Moradi, Maedeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Research Institute of Tuberculosis and Lung Disease 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978031/
https://www.ncbi.nlm.nih.gov/pubmed/35382080
_version_ 1784680894484709376
author Sharif-Kashani, Babak
Serati, Alireza
Shafaghi, Shadi
Behzadnia, Neda
Naghashzadeh, Farah
Keshmiri, Mohammad Sadegh
Moradi, Maedeh
author_facet Sharif-Kashani, Babak
Serati, Alireza
Shafaghi, Shadi
Behzadnia, Neda
Naghashzadeh, Farah
Keshmiri, Mohammad Sadegh
Moradi, Maedeh
author_sort Sharif-Kashani, Babak
collection PubMed
description Pulmonary artery hypertension (PAH) occurs when mean pulmonary artery pressure (PAP) is higher than 25 mmHg in rest or 30 mmHg during activity. Idiopathic pulmonary artery hypertension (IPAH) is defined as PAH without a definite reason. The IPAH is a rare disease with a high mortality rate if left untreated. To date, there has been no definite cure for this entity, and most treatments are for symptom relief or improvement in the quality of life. For many years, decompressing the right heart through a hole in the interatrial septum has been advised to alleviate some of their symptoms, specifically syncope. Atrial flow regulator (AFR) is a device to make an iatrogenic interatrial hole and finally a unidirectional shunt. It has been used for some PAH patients for symptom relief. Herein, we report a 36-year-old female case with diagnosed IPAH for 6 years. In the last 3 years, the case had frequent syncope with shortening intervals. The AFR was implanted for her without any complications. Then, within 6 months of follow-up, she had only one syncope episode. A significant change was observed in her 6-minute walk and PAP.
format Online
Article
Text
id pubmed-8978031
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher National Research Institute of Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-89780312022-04-04 Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator Sharif-Kashani, Babak Serati, Alireza Shafaghi, Shadi Behzadnia, Neda Naghashzadeh, Farah Keshmiri, Mohammad Sadegh Moradi, Maedeh Tanaffos Case Report Pulmonary artery hypertension (PAH) occurs when mean pulmonary artery pressure (PAP) is higher than 25 mmHg in rest or 30 mmHg during activity. Idiopathic pulmonary artery hypertension (IPAH) is defined as PAH without a definite reason. The IPAH is a rare disease with a high mortality rate if left untreated. To date, there has been no definite cure for this entity, and most treatments are for symptom relief or improvement in the quality of life. For many years, decompressing the right heart through a hole in the interatrial septum has been advised to alleviate some of their symptoms, specifically syncope. Atrial flow regulator (AFR) is a device to make an iatrogenic interatrial hole and finally a unidirectional shunt. It has been used for some PAH patients for symptom relief. Herein, we report a 36-year-old female case with diagnosed IPAH for 6 years. In the last 3 years, the case had frequent syncope with shortening intervals. The AFR was implanted for her without any complications. Then, within 6 months of follow-up, she had only one syncope episode. A significant change was observed in her 6-minute walk and PAP. National Research Institute of Tuberculosis and Lung Disease 2021-03 /pmc/articles/PMC8978031/ /pubmed/35382080 Text en Copyright© 2021 National Research Institute of Tuberculosis and Lung Disease https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Case Report
Sharif-Kashani, Babak
Serati, Alireza
Shafaghi, Shadi
Behzadnia, Neda
Naghashzadeh, Farah
Keshmiri, Mohammad Sadegh
Moradi, Maedeh
Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator
title Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator
title_full Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator
title_fullStr Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator
title_full_unstemmed Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator
title_short Curable Syncope in Primary Pulmonary Hypertension with Novel Atrial Flow Regulator
title_sort curable syncope in primary pulmonary hypertension with novel atrial flow regulator
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978031/
https://www.ncbi.nlm.nih.gov/pubmed/35382080
work_keys_str_mv AT sharifkashanibabak curablesyncopeinprimarypulmonaryhypertensionwithnovelatrialflowregulator
AT seratialireza curablesyncopeinprimarypulmonaryhypertensionwithnovelatrialflowregulator
AT shafaghishadi curablesyncopeinprimarypulmonaryhypertensionwithnovelatrialflowregulator
AT behzadnianeda curablesyncopeinprimarypulmonaryhypertensionwithnovelatrialflowregulator
AT naghashzadehfarah curablesyncopeinprimarypulmonaryhypertensionwithnovelatrialflowregulator
AT keshmirimohammadsadegh curablesyncopeinprimarypulmonaryhypertensionwithnovelatrialflowregulator
AT moradimaedeh curablesyncopeinprimarypulmonaryhypertensionwithnovelatrialflowregulator